Biotron have reported a 100% cure rate for Hepatitis C patients in trials of their lead drug.
By contrast, the USA developer of Hepatitis C drugs, Idenix Pharmaceuticals, had demonstrated a cure rate of about 90% for their lead drug in June 2014.
In June 2014, Idenix Pharmaceuticals was taken over by Merck for $US3.85 billion. (About $A4.9billion)
At the time of the takeover, the main Idenix drug had been trialled on less than 100 patients, which makes it an even earlier stage trial drug than the more successful Biotron drug, with Biotron dosing over 180 patients to November 2014.
No one can know the likelihood that any similar takeover will ever eventuate for Biotron, nor the possible price, but I note that even if the Idenix takeover value of $A4.9billion were to be scaled down by 90% for such unknowns, to say 10% of the value paid by Merck, then Biotron shares would be selling for over $A1.60.
GLTA
All trial Patients Dosed , no news is good news !
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
